Clinical Trials Browser

Phase 3 × eribulin × 30 days × Clear all

NCT07461454 2026-03-10

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Phase 3 Not yet recruiting

Breast Neoplasms